The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Product Name	Package Size	NDC	Lot	Exp Date	Manufacturer Initial Ship Date
Lidocaine Hydrochloride Jelly USP, 2%	Pack of 10 x 5ml Tubes	17478-711-31 (Carton) 17478-711-10 (Tubes)	**9J36A**	**8/31/2022**	**6/15/2020**
			9J36B	**8/31/2022**	**5/27/2020**
			9J39A	**8/31/2022**	**11/26/2019**
			9J39B	**8/31/2022**	**1/3/2020**
			9J39C	**8/31/2022**	**12/20/2019**
			9J39O	**8/31/2022**	**12/20/2019**
			9J39E	**8/31/2022**	**1/7/2020**
			9J42B	**8/31/2022**	**1/28/2020**
			9J42C	**8/31/2022**	**1/30/2020**
			9K62A	**9/30/2022**	**3/16/2020**
			9K62B	**9/30/2022**	**7/17/2020**
			9K62C	**9/30/2022**	**7/17/2020**
			9M04A	**11/30/2022**	**3/31/2020**
			9M04B	**11/30/2022**	**3/31/2020**
Sodium Chloride Ophthalmic Ointment USP, 5%	3.5g Tube	17478-622-35	**9J58A** **9J58B**	**8/31/2022** **8/31/2022**	**12/13/2019** **12/18/2019**

This recall notice is from Akorn Specialty Generics. This voluntary recall is prompted by the identification of turbidity during sterility testing for a product manufactured on Fill Line #2. Akorn's expansion of the investigation has indicated that while additional products/lots were manufactured on the same line during the investigated timeframe, the assessment of sterility results for the batches listed above showed passing sterility results. Akorn's review of the environmental data associated with these batches showed no recoveries and no significant shifts or negative trends observed that would indicate systemic microbial contamination. Nonetheless, as a precautionary matter, Akorn is initiating a recall for all lots manufactured on Fill line #2 during the investigated timetrame and within expiry.

This recall is being carried out at the RETAIL level and is only for the specific lots listed above.